Trial reportArthritis research & therapy2012
Fractional clearance of urate: validation of measurement in spot-urine samples in healthy subjects and gouty patients.
Trial report in Arthritis research & therapy, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 39 citations in OpenAlex.
- Trial
- The Effect of Lesinurad in Combination With Allopurinol on Serum Uric Acid Levels in Patients With Gout.Journal of clinical pharmacology · 2018Trial
- Reference intervals of urinary clearance and excretion of uric acid (RICE-U) in Japan.European journal of nutrition · 2026Observational
- Response to Allopurinol and Febuxostat According to the Fractional Excretion of Urate in Men With Gout.Arthritis care & research · 2026Article
- SLC52A1 is a neofunctionalized primate urate transporter enabling intestinal urate secretion.The Journal of biological chemistry · 2026Article
- Association between urinary uric acid excretion and kidney outcome in patients with CKD.Scientific reports · 2024Article
- The Uricosuric Effect of SGLT2 Inhibitors Is Maintained in the Long Term in Patients with Chronic Kidney Disease and Type 2 Diabetes Mellitus.Journal of clinical medicine · 2024Article
- Extract ofFood science and biotechnology · 2022Article
- Association of uric acid with kidney function and albuminuria: the Uric Acid Right for heArt Health (URRAH) Project.Journal of nephrology · 2022Article
- Clinical classification of hyperuricemia in patients with chronic kidney disease.International urology and nephrology · 2021Article
- A pharmacokinetic-pharmacodynamic study of a single dose of febuxostat in healthy subjects.British journal of clinical pharmacology · 2020Article
- Comparison of fractional excretion of electrolytes in patients at different stages of chronic kidney disease: A cross-sectional study.Medicine · 2020Observational
- Population-specific factors associated with fractional excretion of uric acid.Arthritis research & therapy · 2019Article
- Urinary excretion of uric acid is negatively associated with albuminuria in patients with chronic kidney disease: a cross-sectional study.BMC nephrology · 2018Article
- The prevalence, subtypes and associated factors of hyperuricemia in lupus nephritis patients at chronic kidney disease stages 1-3.Oncotarget · 2017Article
- Effect of xanthine oxidase inhibitors on the renal clearance of uric acid and creatinine.Clinical rheumatology · 2016Article
- Comorbidity Burden in Trial-Aligned Patients with Established Gout in Germany, UK, US, and France: a Retrospective Analysis.Advances in therapy · 2016Observational
- New gout test: enhanced ex vivo cytokine production from PBMCS in common gout patients and a gout patient with Kearns-Sayre syndrome.Clinical rheumatology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionHyperuricemia is the greatest risk factor for gout and is caused by an overproduction and/or inefficient renal clearance of urate. The fractional renal clearance of urate (FCU, renal clearance of urate/renal clearance of creatinine) has been proposed as a tool to identify subjects who manifest inefficient clearance of urate. The aim of the present studies was to validate the measurement of FCU by using spot-urine samples as a reliable indicator of the efficiency of the kidney to remove urate and to explore its distribution in healthy subjects and gouty patients.
methodsTimed (spot, 2-hour, 4-hour, 6-hour, 12-hour, and 24-hour) urine collections were used to derive FCU in 12 healthy subjects. FCUs from spot-urine samples were then determined in 13 healthy subjects twice a day, repeated on 3 nonconsecutive days. The effect of allopurinol, probenecid, and the combination on FCU was explored in 11 healthy subjects. FCU was determined in 36 patients with gout being treated with allopurinol. The distribution of FCU was examined in 118 healthy subjects and compared with that from the 36 patients with gout.
resultsNo substantive or statistically significant differences were observed between the FCUs derived from spot and 24-hour urine collections. Coefficients of variation (CVs) were both 28%. No significant variation in the spot FCU was obtained either within or between days, with mean intrasubject CV of 16.4%. FCU increased with probenecid (P < 0.05), whereas allopurinol did not change the FCU in healthy or gouty subjects. FCUs of patients with gout were lower than the FCUs of healthy subjects (4.8% versus 6.9%; P < 0.0001).
conclusionsThe present studies indicate that the spot-FCU is a convenient, valid, and reliable indicator of the efficiency of the kidney in removing urate from the blood and thus from tissues. Spot-FCU determinations may provide useful correlates in studies investigating molecular mechanisms underpinning the observed range of efficiencies of the kidneys in clearing urate from the blood.
trial registrationACTRN12611000743965.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.